Compare KTOS & BBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KTOS | BBIO |
|---|---|---|
| Founded | 1994 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Military/Government/Technical | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 14.5B | 15.3B |
| IPO Year | 1999 | 2019 |
| Metric | KTOS | BBIO |
|---|---|---|
| Price | $75.77 | $72.59 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 17 | 25 |
| Target Price | ★ $97.44 | $83.96 |
| AVG Volume (30 Days) | ★ 4.0M | 2.0M |
| Earning Date | 05-06-2026 | 04-28-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 18.18 | N/A |
| EPS | ★ 0.13 | N/A |
| Revenue | ★ $751,900,000.00 | $502,076,000.00 |
| Revenue This Year | $25.63 | $88.16 |
| Revenue Next Year | $23.29 | $74.13 |
| P/E Ratio | $615.38 | ★ N/A |
| Revenue Growth | 12.44 | ★ 126.26 |
| 52 Week Low | $27.51 | $28.33 |
| 52 Week High | $134.00 | $84.94 |
| Indicator | KTOS | BBIO |
|---|---|---|
| Relative Strength Index (RSI) | 36.35 | 55.68 |
| Support Level | $70.49 | $70.65 |
| Resistance Level | $81.53 | $78.83 |
| Average True Range (ATR) | 5.12 | 2.88 |
| MACD | -1.17 | 0.52 |
| Stochastic Oscillator | 2.85 | 70.89 |
Kratos Defense & Security Solutions Inc develops and fields transformative, affordable technology, platforms, and systems. The company has two segments; The Kratos Government Solutions (KGS) segment is comprised of an aggregation of KGS operating segments, including its microwave electronic products, space, training, and cybersecurity, C5ISR/modular systems, turbine technologies, and defense and rocket support services operating segments and The Unmanned Systems segment consists of unmanned aerial, unmanned ground, unmanned seaborne and related command, control, and communications system businesses. The company derives a majority of its revenue from the Kratos Government Solutions segment.
BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis), is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.